| First Author | Crespo J | Year | 2021 |
| Journal | PLoS One | Volume | 16 |
| Issue | 2 | Pages | e0245917 |
| PubMed ID | 33596227 | Mgi Jnum | J:305166 |
| Mgi Id | MGI:6508369 | Doi | 10.1371/journal.pone.0245917 |
| Citation | Crespo J, et al. (2021) A humanized CD3epsilon-knock-in mouse model for pre-clinical testing of anti-human CD3 therapy. PLoS One 16(2):e0245917 |
| abstractText | Pre-clinical murine models are critical for translating drug candidates from the bench to the bedside. There is interest in better understanding how anti-human CD3 therapy works based on recent longitudinal studies of short-term administration. Although several models have been created in this pursuit, each have their own advantages and disadvantages in Type-1 diabetes. In this study, we report a murine genetic knock-in model which expresses both a murine and a humanized-CD3epsilon-exon, rendering it sensitive to manipulation with anti-human CD3. These huCD3epsilonHET mice are viable and display no gross abnormalities. Specifically, thymocyte development and T cell peripheral homeostasis is unaffected. We tested immune functionality of these mice by immunizing them with T cell-dependent antigens and no differences in antibody titers compared to wild type mice were recorded. Finally, we performed a graft-vs-host disease model that is driven by effector T cell responses and observed a wasting disease upon transfer of huCD3epsilonHET T cells. Our results show a viable humanized CD3 murine model that develops normally, is functionally engaged by anti-human CD3 and can instruct on pre-clinical tests of anti-human CD3 antibodies. |
